Abstract 46P
Background
ABCB1 gene reported to affect chemo-induced toxicity through drug disposition and efflux mechanisms. This study aims to evaluate the influence of ABCB1 (C1236T, G2677T/A, C3435T) polymorphisms on, chemotoxicity, and survival outcomes in BC patients treated with anthracycline and taxane either sequentially or concomitantly.
Methods
100 patients were included who received sequential or concomitant anthracycline and taxane as per clinician discretion and underwent modified radical mastectomy. Chemotoxicity grade was analyzed by CTCAE v.4. All patients received standard premedication with 5HT3, NK1 receptor antagonist, dexamethasone, H2 blocker/ PPI. SNP of ABCB1 (C1236T, G2677T/A, C3435T) gene was detected by PCR-RFLP and sequencing.
Results
Patients mostly reported at Stage III (52.89%) with infiltrating ductal carcinoma subtype (90.9%) who received sequential (50%) & concomitant (50%) chemotherapy. Grade ≥2 chemo toxicity like neutropenic fever, significantly associated with C1236T SNP with odd ratio (OR) for TT genotypes was 2.00 (95% CI: 0.125-31.975, p=0.000), while in CT genotypes, it stood at 1.100 (95% CI: 0.063-15.988; p = 0.035). Meanwhile, vomiting was significantly associated with C3435T for TT genotypes, with an OR of 3.031 (95% CI: 0.031-7.994, p=0.05). TT genotypes (C1236T) were significantly associated with nausea (OR: 2.667; 95% CI: 1.043-6.815; p = 0.04). Alopecia was observed 88% patients. However, ABCB1 showed no significant (p = 0.416, Log-rank) correlation for overall survival. Although, no significant associations were found for G2677T/A in terms of toxicity and survival.
Conclusions
The homozygous mutant TT genotypes (C1236T and C3435T) and heterozygous CT genotypes (C1236T) showed significant association to chemo-induced toxicity (hematological toxicity, nausea, vomiting, alopecia) in patients underwent anthracycline and taxane. Hence, these SNPs could serve as predictive markers to mitigate chemotherapy's adverse effects and optimize treatment to reduce the grade of toxicity and improves patients quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
V. D. Nasare.
Funding
This work is funded by Council of Scientific and Industrial Research, Government of India, File No. 09/030(0085)/2019-EMR-I awarded to Tanuma Mistry.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
540P - Phase III study of serplulimab plus chemotherapy as first-line therapy for advanced squamous non-small cell lung cancer: ASTRUM-004 Asian subgroup
Presenter: Caicun Zhou
Session: Poster Display
Resources:
Abstract
541P - Integrated analysis of randomized controlled trials IMpower130 and IMpower132 for advanced non-squamous non-small cell lung cancer (NSCLC)
Presenter: Hibiki Udagawa
Session: Poster Display
Resources:
Abstract
542P - First-line HLX07 plus serplulimab with or without chemotherapy versus serplulimab plus chemotherapy in advanced/recurrent squamous non-small cell lung cancer: A phase II study
Presenter: Zhen Wang
Session: Poster Display
Resources:
Abstract
543P - A multicenter retrospective study to investigate risk factors for immune checkpoint inhibitor-induced pneumonitis in non-small cell lung cancer patients with comorbid interstitial pneumonia
Presenter: Yuriko Ishida
Session: Poster Display
Resources:
Abstract
544P - Single cell level investigation of blood cells representing immune checkpoint inhibitor response in lung adenocarcinoma patients
Presenter: Juyong Seong
Session: Poster Display
Resources:
Abstract
545P - Completion of pembrolizumab in advanced non-small cell lung cancer: Real-world outcomes after two years of therapy (COPILOT)
Presenter: Andrew Fantoni
Session: Poster Display
Resources:
Abstract
546P - Combination therapy with anti-PD-1 antibody plus angiokinase inhibitor exerts synergistic antitumor effect against malignant mesothelioma via tumor microenvironment modulation
Presenter: Akio Tada
Session: Poster Display
Resources:
Abstract
547P - Immunotherapy outcome in advanced/metastatic lung cancer patients in real-world experience: Indian data
Presenter: Naveen K
Session: Poster Display
Resources:
Abstract
548P - B-Myb acts as a mentor instant promoter in non-small cell lung cancer by modifying the PD-1/PD-L1 axis
Presenter: Pan Xu
Session: Poster Display
Resources:
Abstract
549P - Drug-induced interstitial lung disease in patients with non-small cell lung cancer treated with immunotherapy for postoperative recurrence: Evaluation of CT findings and histopathological findings of the background lung
Presenter: shodai fujimoto
Session: Poster Display
Resources:
Abstract